Padcev is approved for use in combination with the programmed death 1 inhibitor Keytruda (pembrolizumab) or Keytruda QLEX (pembrolizumab and berahyaluronidase alfa-pmph) as neoadjuvant treatment and ...
For individuals facing fear, uncertainty and repeated procedures associated with recurrent low-grade intermediate-risk bladder tumors, timely access to treatment can be critical. ZUSDURI, the first ...
Urogynecologist Judy Yeh, MD, FACOG and the Tift Regional Medical Center operating room team conducted the first Altaviva ...
Discover the top 3 undervalued Health Care Equipment & Supplies stocks for Friday, January 02 based on AAII’s Stock Grades.
TipRanks on MSN
Relmada’s BOOST phase 3 bladder cancer trial sets up a new catalyst for RLMD investors
Relmada Therapeutics Inc ($RLMD) announced an update on their ongoing clinical study. Relmada Therapeutics is preparing to launch a late-stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback